Hangzhou Tigermed Consulting Co., Ltd is a China-based contract research organization (CRO) providing comprehensive biopharmaceutical R&D services. Established in 2004, the company offers end-to-end solutions covering preclinical development, early-phase and Phase II-III clinical trials, post-marketing studies, and real-world studies. Its service portfolio includes clinical development strategy, data management, statistical analysis, decentralized clinical trials, multi-region clinical trials, and functional service provider capabilities. The company serves the global biopharmaceutical and medical device industries, supporting the development of small molecules, biologics, vaccines, and medical devices. It operates a global network with offices across Asia Pacific, Europe, North America, South America, and Africa. Key subsidiaries include Shanghai Bioquick Pharmaceutical Supply Chain Management Co., Ltd., JetMed (Beijing) Co., Ltd., Hangzhou Tigermed-IntelliPV Co., Ltd., Jiaxing Tigermed Data Management Co., Ltd., Tigermed Xinze Medical Technology (Jiaxing) Co., Ltd., and MacroStat (China) Clinical Research Co., Ltd. The company has formed strategic partnerships with entities such as Veeda Lifesciences and has supported major clients including Pfizer, AstraZeneca, and MSD.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Diagnostics & Research Homepage tigermedgrp.com
Sector Healthcare IR page tigermedgrp.com/en/investors
Tags
clinical research organization, biopharmaceutical r&d, clinical trials, preclinical development, data management, statistical analysis, decentralized clinical trials, multi-region clinical trials, real-world studies, medical device development, Shanghai Bioquick Pharmaceutical Supply Chain Management Co. Ltd., JetMed (Beijing) Co. Ltd., Hangzhou Tigermed-IntelliPV Co. Ltd., Jiaxing Tigermed Data Management Co. Ltd., Tigermed Xinze Medical Technology (Jiaxing) Co. Ltd., MacroStat (China) Clinical Research Co. Ltd., Veeda Lifesciences
Press page tigermedgrp.com/zh-hant/media-resources/press-releases

Metrics

Valuation  
Market cap HK$ 28.535B
Market cap (USD) $ 3.637B
P/E 28.68
PEG —
P/BV 0.99
P/S 3.33
P/OCF 21.36
P/FCF —
Dividend yield 0.43%
Turnover / mcap 0.11%
Returns  
ROE —
ROI 72.3%
ROIC 72.7%
Profit margin 11.8%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -26.4%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -12.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 6.833B 6.603B 7.384B 7.085B 5.214B 3.192B 2.803B
Net profit 805.056M 447.831M 2.027B 2.016B 2.879B 1.751B 841.247M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 37.51 26.04 39.1 109.37 69.79 176.27 —
Price performance 12m 0.47 -0.33 -0.66 0.49 -0.58 — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Hangzhou Tigermed Consulting Co., Ltd (ticker 3347), listed in Hong Kong.

ETFs Holding Hangzhou Tigermed Consulting Co., Ltd

ETF Weight in ETF Shares Market value As of
DFSE 0.01% 16,800 $ 81.466K Nov 12, 2026
DFEM 0.01% 146,400 $ 709.918K Nov 12, 2026
NTSE 0.01% 800 $ 3,546.01 Jun 30, 2026
DFAE 0.00% 73,900 $ 358.353K Nov 12, 2026
DFAX 0.00% 57,700 $ 279.797K Nov 12, 2026
AVEM 0.00% 23,800 $ 106.553K Nov 16, 2026
AVSE 0.00% 500 $ 2,238.51 Nov 16, 2026